期刊文献+

卡维地洛治疗慢性心衰的疗效及对血浆脑钠肽水平的影响 被引量:4

下载PDF
导出
摘要 目的对比研究卡维地洛治疗慢性心衰的疗效及对患者血浆脑钠肽水平的影响。方法随机抽取2010年9月至2011年9月于我科就诊的慢性心力衰竭患者80例,随机均分为实验组及对照组各40例,对照组使用常规治疗,实验组在此基础上加用卡维地洛,所有患者治疗前及治疗结束后均进行心功能评级、心脏彩超检查和血浆BNP测试。结果治疗结束后,两组患者心功能均有改善,但实验组总有效率为92.5%,显著高于对照组,差异有统计学意义(P<0.05);实验组及对照组组内对比治疗后LVEDd、BNP均显著下降,LVEF均显著上升,差异均有统计学意义(P<0.05);实验组治疗后LVEDd、LVEF、BNP改变较对照组更为明显,组间差异具有统计学意义(P<0.05)。结论血浆脑钠肽可以作为治疗慢性心力衰竭的疗效判断指标;卡维地洛治疗慢性心力衰竭有着良好的疗效,能显著改善慢性心衰患者的心功能,降低BNP浓度,改善患者预后。
作者 周云
出处 《海峡药学》 2013年第2期90-92,共3页 Strait Pharmaceutical Journal
  • 相关文献

参考文献10

  • 1FAGGIANO P,VALLE R,ASPROMONTE N,et al. How often we need to measure brain natriuretic peptide(BNP) blood levels in patients ad- mined to the hospital for acute severeheart failure Role of serial meas- urements to improve short-term prognostic stratification[ J]. Int J Car- dio1,2010,140 ( 1 ) :88-94.
  • 2慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2413
  • 3BHASKAR E. BNP-guided heart failure therapy in older patients [ J ]. JAMA,2009,301 (20) :2091-2092.
  • 4KOUREA K, PARISSIS JT, FARMAKIS D, et al. Effects of darbepoet in-alpha on plasma pro-inflammatory cytok in es, anti-inflammatory cy- tokine interleukin-10 and soluble Fas/Fas ligand system in anemic pa- tients with chronic heart failure [J]. Atherosclerosis, 2008,199 ( 1 ) : 215-221.
  • 5GROOTE P, DELOUR P, MOUQUET F, et al. The effects of betablock- ers in patients with stable chronic heart failure. Predictors of left ven- tricular ejection fraction improvement and impact on prognosis[ J]. Am Heart J ,2007,154 ( 3 ) :589-595.
  • 6Doughty RN, White HD. Carvedilol use in chronicheart failure [J] . Expert Rev Cardiovasc Ther,2007,5( 1 ) :21-31.
  • 7Vuolteenaho O ,Ala-Kopsala M, Ruskoaho H. BNP as a bio-marker in heart disease[J]. Adv Clin Chem,2005,40( 1 ) :1-36.
  • 8KALLISTRATOS MS, DRITSAS A, LAOUTARIS 1D, et al. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol [ J]. Angiology, 2008.59(3 ) :323-328.
  • 9王咏梅,周发展,吴云.卡维地洛治疗充血性心力衰竭对血浆脑钠肽水平的影响[J].中国医药,2008,3(1):20-21. 被引量:15
  • 10赖长春,高伟栋,李浙成,应显星,胡智星,童跃锋.慢性心力衰竭时脑钠肽和C反应蛋白水平及卡维地洛的疗效[J].岭南心血管病杂志,2007,13(5):340-343. 被引量:21

二级参考文献9

  • 1杜林林,王朝晖.卡维地洛对TNF-α诱导心肌细胞凋亡的保护作用[J].中国临床药理学与治疗学,2005,10(11):1286-1289. 被引量:1
  • 2[2]RICHARDS A M,DOUGHTY R,NICHOLLS MG,et al.Nerurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction[J].Circulation,1999,99 (6):786-792.
  • 3[3]GABAY C,KUSHNER I.Acute-phase proteins and other systemic responses to inflammation[J].N Engl J Med,1999,340 (6):448-454.
  • 4[4]SUFFREDINI A F,FROMM R E,PARKER M M,et al.The cardiovascular response of normal humans to the administration of endotoxin[J].N Engl J Med,1989,321(5):280-287.
  • 5[5]SAM F,SAWYER D B,CHANG D L,et al.Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart[J].Am J Physiol Heart Circ Physiol,2000,279 (1):H422-H428.
  • 6[6]ALONSO-MARTINEZ J L,LLORENTE-DIEZ B,ECHEGARAY-AGARA M,et al.C-reactive protein as a predictor of improvement and readmission in heart failure[J].Eur J Heart Fail,2002,49 (3):331-336.
  • 7[7]TORRE A G,KAPADIA S,BENEDICT C,et al.Proin flammatory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the studies of left ventricular dysfunction (SOLVD)[J].Am Coll Cardiol,1996,27 (5):1201-1206.
  • 8Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
  • 9慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2413

共引文献2442

同被引文献29

引证文献4

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部